Saturday 17 October 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025. In the quarter to September 2025, EPS fell 609.4% and free cash flow fell 26.5%, each against the same quarter a year earlier.
0.34
0.00
0.00%
Follow ALPS
| Dec '17 | Jan '21 | Dec '21 | Jan '22 | Dec '22 | Dec '23 | Mar '24 | Dec '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | — | 144.15 | — | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
P/FCF ratio |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | — | — | — | — | — | — | (1.64) |
P/Operating CF |
— | — | — | — | — | — | (42.66) | — | (258.37) | (13.76) |
P/B ratio |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
EV/EBITDA |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | — | (17.11) | — | (31.47) | (3.21) |
EV/FCF |
— | — | — | — | — | — | (17.11) | — | (31.47) | (3.21) |
Quick Ratio |
— | 3.52 | 3.52 | 0.11 | 0.11 | 0.02 | — | 0.04 | 0.08 | 0.15 |
Current Ratio |
— | 4.46 | 4.46 | 0.37 | 0.37 | 0.05 | — | 0.05 | 0.20 | 0.36 |
Net Debt/EBITDA |
— | 5.99 | 5.99 | 0.06 | 0.06 | 0.07 | 0.00 | 0.15 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.62 | 0.69 |
Operating CF/Net income |
— | 2.72 | 2.72 | (3.26) | (3.26) | (1.06) | 0.59 | 2.08 | 0.64 | 1.28 |
Capex/Depreciation |
— | — | — | — | — | — | (0.24) | — | (0.07) | (0.05) |
Interest Coverage |
— | (2,714.00) | — | 0.00 | — | (20.52) | — | (9.10) | — | — |
| — | 0.00% | (0.22%) | 0.00% | (6.24%) | (23.33%) | 0.00% | 10.90% | 42.60% | 92.43% | |
| — | (0.20%) | (0.10%) | 0.00% | 0.19% | 1.79% | (15.96%) | (6.01%) | (46.40%) | (28.48%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
— | (14.97%) | (14.97%) | (46.03%) | (46.03%) | (33.29%) | 0.00% | 14.42% | 69.42% | 149.88% |
Average Days of Receivables |
— | — | — | — | — | — | 0.00 | — | 64.68 | 63.68 |
Research and Development Expense of Revenue |
— | — | — | — | — | — | 0.00% | — | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 80.28% | 0.00% | 71.22% | 72.02% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.10 | 0.09 |
Share Based Compensation of Revenue |
— | — | — | — | — | — | 0.00% | — | 0.00% | 0.00% |
Graham Net Nets |
— | — | — | — | — | — | (0.98) | — | (0.34) | (3.93) |
Graham Number |
— | — | — | — | — | — | 0.00 | — | 4.97 | — |
Earnings Yield |
— | — | — | — | — | — | 0.69% | — | (2.96%) | (75.81%) |
Free Cash Flow Yield |
— | — | — | — | — | — | (5.84%) | — | (3.18%) | (27.94%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.02 | 0.03 |
Operating CF per Share |
— | (0.02) | (0.11) | (0.05) | (0.21) | (0.41) | (0.01) | (0.59) | (0.01) | (0.02) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.02) | (0.11) | (0.05) | (0.21) | (0.41) | (0.01) | (0.59) | (0.01) | (0.02) |
Cash per Share |
— | 0.05 | 0.28 | 0.01 | 0.02 | 0.02 | 0.00 | 0.07 | 0.00 | 0.00 |
Shareholders Equity per Share |
— | 7.60 | (1.08) | 7.62 | (1.18) | (2.11) | 0.00 | (3.10) | (0.01) | (0.02) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 7.60 | (1.08) | 7.62 | (1.18) | (2.11) | 0.00 | (3.10) | (0.01) | (0.02) |
Free Cash Flow |
— | (0.32) | (0.32) | (0.73) | (0.73) | (1.40) | (1.59) | (2.04) | (1.69) | (2.63) |
Working Capital |
— | 0.80 | 0.80 | (0.49) | (0.49) | (3.97) | — | (6.78) | (6.00) | (3.50) |
Capital Expenditures |
— | — | — | — | — | — | (0.22) | — | (0.08) | (0.06) |
Net Current Asset Value |
— | (3.34) | (120.07) | (4.68) | (122.46) | (35.93) | — | (14.04) | (6.76) | (8.22) |
EV/EBIT |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
Capex to Sales |
— | — | — | — | — | — | 0.09 | — | 0.02 | 0.01 |
Price to Operating Income |
— | — | — | — | — | — | 0.00 | — | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
— | — | — | — | — | — | 0.00 | — | 0.47 | 0.52 |
Cash ROIC |
— | (0.28%) | 13.97% | (0.64%) | 18.39% | 19.52% | 0.00% | 19.55% | 151.68% | 81.49% |
Accounts Receivable Turnover |
— | — | — | — | — | — | 0.00 | — | 0.00 | 6.72 |
Accounts Payable Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 10.32 | 9.83 |
Inventory Turnover |
— | — | — | — | — | — | 0.00 | — | 0.00 | 6.29 |
Average Days of Payables |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 56.68 | 38.71 |
Days of Inventory on Hand |
— | — | — | — | — | — | 0.00 | — | 98.08 | 54.55 |
Average Receivables |
— | — | — | — | — | — | — | — | — | 0.72 |
Average Payables |
— | — | — | — | 0.16 | 0.16 | — | 0.11 | 0.20 | 0.34 |
Average Inventory |
— | — | — | — | — | — | — | — | — | 0.52 |
Average Assets |
— | 58.98 | 117.96 | 118.37 | 118.33 | 73.79 | 14.44 | 16.29 | 5.42 | 7.05 |
Average Common Equity |
— | — | 55.22 | 55.34 | (3.60) | (5.66) | — | (8.97) | (5.90) | (2.17) |
Columns are period end dates